Essential Medicines List Explained for Beginners... Pharmacyteach

Essential Medicines List Explained for Beginners

What Is an Essential Medicines List (EML)?

Imagine walking into a healthcare facility and knowing that the most important medicines needed to treat common and serious diseases are available, affordable, and safe. That simple idea is the foundation of the Essential Medicines List (EML). An Essential Medicines List is a carefully selected collection of medicines considered necessary to meet the priority healthcare needs of a population. These medicines are chosen based on scientific evidence, safety, effectiveness, and their ability to provide the greatest public health benefit. According to the, essential medicines should be available at all times in adequate quantities, in appropriate dosage forms, and at prices individuals and health systems can afford.

The concept may sound simple, but it has transformed healthcare worldwide. Think of the EML as a healthcare system's "must-have" checklist. Just as a firefighter needs essential tools to respond to emergencies, healthcare systems need essential medicines to address common diseases, infections, chronic conditions, and life-threatening illnesses. By focusing resources on medicines that provide the greatest benefit, governments can improve access, reduce costs, and ensure better treatment outcomes for millions of people. Today, the EML remains one of the most influential public health tools ever developed, guiding medicine procurement, reimbursement policies, and healthcare planning across the globe.

Definition of Essential Medicines

Essential medicines are drugs that satisfy the priority healthcare needs of a population. They are selected through a rigorous evaluation process that examines disease prevalence, public health importance, scientific evidence, safety profiles, and cost-effectiveness. Unlike the thousands of medicines available on the pharmaceutical market, only those that provide significant health benefits and address major health concerns are considered essential.

Why the Concept Was Created

Before the introduction of the EML, many countries struggled with medicine shortages, irrational prescribing practices, and inefficient healthcare spending. Governments often purchase large numbers of medicines without prioritizing those that offer the greatest public health impact. The Essential Medicines concept was created to help countries focus on medicines that truly matter, ensuring that limited healthcare resources are used wisely and effectively.

Learn About: List of antibacterial drugs 

History of the Essential Medicines List

The story of the Essential Medicines List begins in 1977 when the World Health Organization introduced the first model list containing approximately 200 medicines. At the time, the idea was revolutionary. Healthcare experts recognized that not every available medicine was equally important and that prioritizing the most effective treatments could dramatically improve healthcare access, especially in low- and middle-income countries. The list became a practical guide for governments seeking to strengthen their healthcare systems while working within limited budgets.

Over the decades, the EML evolved alongside medical science. New diseases emerged, treatment guidelines changed, and innovative therapies became available. The WHO continuously reviewed and updated the list to reflect these developments. What started as a relatively small collection of medicines has grown into a comprehensive resource covering treatments for infectious diseases, cardiovascular conditions, diabetes, cancer, mental health disorders, and many other health conditions. The expansion reflects both scientific progress and the changing healthcare needs of populations worldwide.

WHO's First List in 1977

The first WHO Model List represented a landmark moment in global public health. It emphasized that access to a carefully selected group of medicines could significantly improve health outcomes while reducing unnecessary healthcare expenditures. The approach quickly gained international support and influenced health policies around the world.

Evolution of the List Over Time

Since 1977, the list has been revised every two years. The WHO has expanded the scope of the list to include new therapeutic areas and emerging health priorities. A separate list for children was introduced in 2007, recognizing the unique healthcare needs of pediatric patients. Today, the EML is considered the global benchmark for medicine selection.

Learn About: Common Drug Interactions and Contraindications Every Doctor Should Know. 

How Medicines Are Selected

One of the most common questions beginners ask is: "How does a medicine become essential?" The answer involves a highly structured and evidence-based process. Medicines are not added because they are popular or heavily marketed. Instead, they must demonstrate clear benefits in terms of safety, effectiveness, and public health impact. Experts carefully review clinical studies, treatment outcomes, adverse effects, and economic factors before making recommendations.

Selection also considers whether a medicine addresses a major health burden. For example, treatments for conditions that affect millions of people worldwide are more likely to be included if they provide meaningful improvements in patient outcomes. Cost-effectiveness is another critical factor. A medicine may be highly effective, but if it is prohibitively expensive and provides only marginal benefits over existing therapies, it may not qualify as essential. This balanced approach helps ensure that the EML remains practical, sustainable, and focused on maximizing public health benefits.

Safety and Effectiveness

The WHO prioritizes medicines with strong scientific evidence supporting their safety and therapeutic effectiveness. Clinical trials, systematic reviews, and real-world data play a crucial role in the evaluation process. Medicines must consistently demonstrate positive outcomes before being considered for inclusion.

Cost-Effectiveness and Public Health Need

Healthcare resources are finite. Therefore, medicines included on the EML must provide substantial value relative to their cost. Public health relevance, disease burden, affordability, and long-term benefits are carefully assessed during the selection process.

Who Creates the Essential Medicines List?

The WHO Model List of Essential Medicines is developed by the Expert Committee on Selection and Use of Essential Medicines. This committee consists of specialists in medicine, pharmacology, public health, epidemiology, and health economics. Their role is to review evidence submitted through an open application process and make recommendations based on objective scientific criteria.

The process is remarkably transparent. Applications for additions, deletions, or modifications can be submitted by governments, healthcare organizations, academic institutions, and professional associations. Experts review the evidence, discuss potential benefits and risks, and determine whether a medicine should be included. This rigorous process helps maintain the credibility and reliability of the list while ensuring that decisions are guided by science rather than commercial interests.

Read About:  Pentavalent Combination Vaccine: A Detailed Overview of DTwP-HepB-Hib.

Role of the World Health Organization

The WHO coordinates the development and updating of the EML, ensuring that the process remains evidence-based, transparent, and globally relevant. The organization also provides technical guidance to countries developing their own national essential medicines lists.

Expert Review Process

The committee reviews applications every two years. In the 2025 update, experts evaluated 59 applications proposing additions, deletions, and modifications to the list. Each application underwent a detailed scientific review before decisions were made.

Structure of the WHO Essential Medicines List

The WHO EML is divided into two major categories: the Core List and the Complementary List. This structure helps countries understand which medicines should be universally available and which may require specialized facilities or expertise. The Core List contains medicines considered essential for a basic healthcare system, while the Complementary List includes medicines that may need specialized diagnostic tools, monitoring, or trained healthcare professionals.

Core List

The Core List includes medicines that are considered the minimum requirements for a functioning healthcare system. These drugs address the most common and important health conditions affecting populations worldwide. Examples include antibiotics, pain relievers, vaccines, and treatments for chronic diseases.

Learn About: Top 10 common Respiratory diseases, treatment, and prevention

Complementary List

The Complementary List contains medicines that may require specialized facilities, advanced training, or additional monitoring. These medicines are often used for complex conditions such as certain cancers or rare diseases.

Essential Medicines for Children

Children are not simply small adults. Their bodies process medicines differently, and they often require different dosages, formulations, and treatment approaches. Recognizing these unique needs, the WHO introduced the Essential Medicines List for Children (EMLc) in 2007. This list focuses specifically on medicines that are safe, effective, and appropriate for pediatric patients.

The EMLc promotes the development and availability of child-friendly formulations such as oral liquids, dispersible tablets, and age-appropriate dosages. It also encourages research into pediatric medicines, helping address historical gaps in evidence and access. Today, the children's list is an essential tool for improving pediatric healthcare worldwide and ensuring that children receive treatments tailored to their unique needs.

Why Children Need a Separate List

A dedicated list helps ensure that children have access to medicines specifically formulated and tested for their age group. This improves safety, effectiveness, and treatment adherence while supporting better healthcare outcomes.

Read About: Why Ringer's lactate solution should be avoided in liver disease?

Benefits of an Essential Medicines List

The benefits of an Essential Medicines List extend far beyond medicine selection. It serves as a strategic tool for healthcare planning, procurement, budgeting, and policy development. By focusing on priority medicines, countries can reduce waste, improve supply chain management, and ensure that critical treatments remain available when needed. This approach also supports rational prescribing practices, helping healthcare providers make evidence-based treatment decisions.

Another major benefit is improved equity. The EML helps ensure that people receive access to important medicines regardless of income or geographic location. It supports universal health coverage goals by identifying treatments that should be available within functioning healthcare systems. More than 150 countries have adopted national essential medicines lists based on the WHO model, demonstrating its widespread influence and effectiveness.

Benefit	Impact
Better Access	Ensures the availability of priority medicines
Lower Costs	Supports efficient procurement
Improved Quality	Focuses on evidence-based treatments
Rational Use	Encourages appropriate prescribing
Health Equity	Expands access across populations

 

Improved Access to Medicines

National EMLs guide medicine procurement and distribution programs, helping healthcare facilities maintain consistent supplies of essential treatments. This reduces shortages and improves patient care.

Read about:  Peptic Ulcer: Causes, Symptoms, and Treatment

Better Healthcare Outcomes

When healthcare systems prioritize proven therapies, patients benefit from safer, more effective treatments. Better access to medicine often translates into a lower disease burden and improved quality of life.

Challenges and Criticisms

Despite its success, the Essential Medicines List faces several challenges. One major issue is affordability. Some newly recommended medicines offer significant health benefits but remain expensive, limiting access in resource-constrained settings. Another challenge involves medicine shortages caused by manufacturing disruptions, supply chain issues, and geopolitical factors. Even when a medicine appears on an EML, availability is not always guaranteed.

Critics also argue that the selection process can be conservative, potentially delaying the inclusion of innovative therapies. Balancing affordability with access to cutting-edge treatments remains a complex challenge. Healthcare leaders continue working to improve procurement systems, encourage generic competition, and strengthen supply chains to ensure that essential medicines reach the people who need them most.

Access and Affordability Issues

High medicine prices remain a significant barrier in many countries. Efforts to promote generic manufacturing and improve procurement strategies are essential for expanding access to critical treatments.

Recent Updates in the WHO Essential Medicines List

The latest WHO update, released in September 2025, introduced several important additions. The current 24th Essential Medicines List and 10th Essential Medicines List for Children reflect evolving healthcare priorities and advances in medical science. The 2025 list contains more than 520 medicines for adults and 374 medicines for children.

Among the most notable additions were GLP-1 receptor agonists and related therapies for Type 2 Diabetes, certain advanced cancer treatments, rapid-acting insulin analogues, and medicines for rare diseases such as cystic fibrosis. WHO experts emphasized that including these medicines may help stimulate broader access and encourage future affordability initiatives. These updates demonstrate how the EML continues to evolve in response to changing health needs and emerging scientific evidence.

Key Changes in the 2025 Update

• Inclusion of GLP-1 medicines for specific Type 2 Diabetes patients.
• Addition of new cancer therapies.
• Expanded access recommendations for insulin analogues.
• Updates to pediatric medicine recommendations.
• Continued refinement of antibiotic stewardship frameworks.

Conclusion

The Essential Medicines List is far more than a catalog of drugs. It is a powerful public health tool that helps countries prioritize healthcare resources, improve access to life-saving treatments, and promote evidence-based medicine. Since its introduction in 1977, the EML has influenced healthcare policy in more than 150 countries and remains one of the most important frameworks for achieving equitable healthcare access worldwide.

For beginners, understanding the EML provides valuable insight into how healthcare systems decide which medicines matter most. Whether you are a student, healthcare professional, policymaker, or simply a curious reader, the Essential Medicines List offers a fascinating example of how science, economics, and public health work together to improve lives across the globe.

FAQs

1. What is the main purpose of the Essential Medicines List?

The main purpose is to identify medicines that address the priority healthcare needs of a population and should be available, affordable, safe, and effective.

2. Who publishes the Essential Medicines List?

The World Health Organization publishes the WHO Model List of Essential Medicines every two years.

3. How often is the WHO EML updated?

The list is updated every two years through an evidence-based expert review process.

4. Why are some medicines not included on the EML?

Medicines may be excluded if they lack sufficient evidence, are not cost-effective, or do not address major public health priorities.

5. Do all countries use the WHO Essential Medicines List?

No, but more than 150 countries use it as a model when developing or updating their own national essential medicines lists.